🎉 M&A multiples are live!
Check it out!

Checkpoint Therapeutics Valuation Multiples

Discover revenue and EBITDA valuation multiples for Checkpoint Therapeutics and similar public comparables like Pharming, Vivoryon Therapeutics, and Galapagos.

Checkpoint Therapeutics Overview

About Checkpoint Therapeutics

Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.


Founded

2014

HQ

United States of America
Employees

24

Financials

LTM Revenue $11.9M

LTM EBITDA -$38.3M

EV

$329M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Checkpoint Therapeutics Financials

Checkpoint Therapeutics has a last 12-month revenue of $11.9M and a last 12-month EBITDA of -$38.3M.

In the most recent fiscal year, Checkpoint Therapeutics achieved revenue of $41K and an EBITDA of -$56.2M.

Checkpoint Therapeutics expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Checkpoint Therapeutics valuation multiples based on analyst estimates

Checkpoint Therapeutics P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue $0.1M $41K XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$52.1M -$56.2M XXX XXX XXX
EBITDA Margin -50629% -137010% XXX XXX XXX
Net Profit -$62.6M -$51.8M XXX XXX XXX
Net Margin -60800% -126456% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Checkpoint Therapeutics Stock Performance

As of April 15, 2025, Checkpoint Therapeutics's stock price is $4.

Checkpoint Therapeutics has current market cap of $336M, and EV of $329M.

See Checkpoint Therapeutics trading valuation data

Checkpoint Therapeutics Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$329M $336M XXX XXX XXX XXX $-1.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Checkpoint Therapeutics Valuation Multiples

As of April 15, 2025, Checkpoint Therapeutics has market cap of $336M and EV of $329M.

Checkpoint Therapeutics's trades at 27.8x LTM EV/Revenue multiple, and -8.6x LTM EBITDA.

Analysts estimate Checkpoint Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Checkpoint Therapeutics and 10K+ public comps

Checkpoint Therapeutics Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $329M XXX XXX XXX
EV/Revenue 8031.4x XXX XXX XXX
EV/EBITDA -5.9x XXX XXX XXX
P/E -6.0x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -10.6x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Checkpoint Therapeutics Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Checkpoint Therapeutics Valuation Multiples

Checkpoint Therapeutics's NTM/LTM revenue growth is 598%

Checkpoint Therapeutics's revenue per employee for the last fiscal year averaged $2K, while opex per employee averaged $2.3M for the same period.

Over next 12 months, Checkpoint Therapeutics's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Checkpoint Therapeutics's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Checkpoint Therapeutics and other 10K+ public comps

Checkpoint Therapeutics Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth -60% XXX XXX XXX XXX
EBITDA Margin -137010% XXX XXX XXX XXX
EBITDA Growth 8% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -136412% XXX XXX XXX XXX
Revenue per Employee $2K XXX XXX XXX XXX
Opex per Employee $2.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 48934% XXX XXX XXX XXX
R&D Expenses to Revenue 88176% XXX XXX XXX XXX
Opex to Revenue 137110% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Checkpoint Therapeutics Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Checkpoint Therapeutics M&A and Investment Activity

Checkpoint Therapeutics acquired  XXX companies to date.

Last acquisition by Checkpoint Therapeutics was  XXXXXXXX, XXXXX XXXXX XXXXXX . Checkpoint Therapeutics acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Checkpoint Therapeutics

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Checkpoint Therapeutics

When was Checkpoint Therapeutics founded? Checkpoint Therapeutics was founded in 2014.
Where is Checkpoint Therapeutics headquartered? Checkpoint Therapeutics is headquartered in United States of America.
How many employees does Checkpoint Therapeutics have? As of today, Checkpoint Therapeutics has 24 employees.
Who is the CEO of Checkpoint Therapeutics? Checkpoint Therapeutics's CEO is Mr. James F. Oliviero, III.
Is Checkpoint Therapeutics publicy listed? Yes, Checkpoint Therapeutics is a public company listed on NAS.
What is the stock symbol of Checkpoint Therapeutics? Checkpoint Therapeutics trades under CKPT ticker.
When did Checkpoint Therapeutics go public? Checkpoint Therapeutics went public in 2016.
Who are competitors of Checkpoint Therapeutics? Similar companies to Checkpoint Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Checkpoint Therapeutics? Checkpoint Therapeutics's current market cap is $336M
What is the current revenue of Checkpoint Therapeutics? Checkpoint Therapeutics's last 12-month revenue is $11.9M.
What is the current EBITDA of Checkpoint Therapeutics? Checkpoint Therapeutics's last 12-month EBITDA is -$38.3M.
What is the current EV/Revenue multiple of Checkpoint Therapeutics? Current revenue multiple of Checkpoint Therapeutics is 27.8x.
What is the current EV/EBITDA multiple of Checkpoint Therapeutics? Current EBITDA multiple of Checkpoint Therapeutics is -8.6x.
What is the current revenue growth of Checkpoint Therapeutics? Checkpoint Therapeutics revenue growth between 2023 and 2024 was -60%.
Is Checkpoint Therapeutics profitable? Yes, Checkpoint Therapeutics is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.